COMy 2021 | The role of the UK in multiple myeloma clinical trials
Gordon Cook
• 30 Apr 2021
Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses advances in myeloma and highlights the central role that the UK plays in driving the field forward. Various trials conducted in the UK including the Myeloma VII, Myeloma IX, Myeloma X, and Myeloma XI trials have been influential in multiple myeloma management. Additional trials discussed include the Myeloma XII trial, the Myeloma XIV trial investigating the International Myeloma Working Group (IMWG) frailty score as a predicative biomarker, as well as an early phase trial assessing B-cell maturation antigen (BCMA) directed therapy. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
